Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: Implication of its potential use as a therapeutic vaccine

Clinical Immunology

Volumn 137, Issue 2, 2010, Pages 190-198

  Zhou, Cheng ^a   Peng, Guoping ^a   Jin, Xiaoli ^a   Tang, Jie ^a   Chen, Zhi ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

CTLA4; DNA vaccine; HBV; Immune response; Transgenic mice

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; VACCINATION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DNA, VIRAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS; TRANSFECTION; VACCINATION; VACCINES, DNA;

EID: 77957296791     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.07.002     Document Type: Article

References (39)

1. Liang T.J. Hepatitis B: the virus and disease. Hepatology 2009, 49:S13-S21.
2. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
3. Liaw Y.F. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J. Hepatol. 2009, 51:403-410.
4. Donnelly J.J., Wahren B., Liu M.A. DNA vaccines: progress and challenges. J. Immunol. 2005, 175:633-639.
5. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 2000, 18:927-974.
6. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:7213-7218.
7. Thermet A., Rollier C., Zoulim F., Trepo C., Cova L. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine 2003, 21:659-662.
8. Fissolo N., Riedl P., Reimann J., Schirmbeck R. DNA vaccines prime CD8+ T cell responses to epitopes of viral antigens produced from overlapping reading frames of a single coding sequence. Eur. J. Immunol. 2005, 35:117-127.
9. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., Culp J., Burkholder J.K., Swain W.F., Dixon R.M., Widera G., Vessey R., King A., Ogg G., Gallimore A., Haynes J.R., Heydenburg Fuller D. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000, 19:764-778.
10. Mancini-Bourgine M., Fontaine H., Brechot C., Pol S., Michel M.L. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006, 24:4482-4489.
11. Kennedy N.J., Spithill T.W., Tennent J., Wood P.R., Piedrafita D. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy. Vaccine 2006, 24:970-979.
12. Chinnasamy D., Tector M., Chinnasamy N., Dennert K., Kozinski K.M., Oaks M.K. A mechanistic study of immune system activation by fusion of antigens with the ligand-binding domain of CTLA4. Cancer Immunol. Immunother. 2006, 55:1504-1514.
13. Tachedjian M., Boyle J.S., Lew A.M., Horvatic B., Scheerlinck J.P., Tennent J.M., Andrew M.E. Gene gun immunization in a preclinical model is enhanced by B7 targeting. Vaccine 2003, 21:2900-2905.
14. Boyle J.S., Brady J.L., Lew A.M. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998, 392:408-411.
15. Nayak B.P., Sailaja G., Jabbar A.M. Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4. J. Virol. 2003, 77:10850-10861.
16. Deliyannis G., Boyle J.S., Brady J.L., Brown L.E., Lew A.M. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6676-6680.
17. Lu M., Isogawa M., Xu Y., Hilken G. Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J. Virol. 2005, 79:6368-6376.
18. Kakimi K., Isogawa M., Chung J., Sette A., Chisari F.V. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 2002, 76:8609-8620.
19. Zheng B.J., Zhou J., Qu D., Siu K.L., Lam T.W., Lo H.Y., Lee S.S., Wen Y.M. Selective functional deficit in dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J. Viral Hepat. 2004, 11:217-224.
20. Chisari F.V., Isogawa M., Wieland S.F. Pathogenesis of hepatitis B virus infection. Pathol. Biol. (Paris) 2010, epub.
21. Schirmbeck R., Bohm W., Ando K., Chisari F.V., Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 1995, 69:5929-5934.
22. Liu G., Xiong Y., Wang H., Jia Y., Zhou J., Pan F., Zhang Y. Establishment of high level expression HBV transgenic BALB/c mice and its genetic and expressive stability. Chin. J. Vet. Sci. 2003, 23:580-582.
23. Stockinger B., Bourgeois C., Kassiotis G. CD4+ memory T cells: functional differentiation and homeostasis. Immunol. Rev. 2006, 211:39-48.
24. Chen A., Wang L., Zhang J., Zou L., Jia Z., Zhou W., Wan Y., Wu Y. H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicity. J. Virol. 2005, 79:5568-5576.
25. Huang Y., Chen Z., Jia H., Wu W., Zhong S., Zhou C. Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg. Clin. Immunol. 2006, 119:280-290.
26. Park D., Lapteva N., Seethammagari M., Slawin K.M., Spencer D.M. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat. Biotechnol. 2006, 24:1581-1590.
27. Peng S., Kim T.W., Lee J.H., Yang M., He L., Hung C.F., Wu T.C. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum. Gene Ther. 2005, 16:584-593.
28. Teft W.A., Kirchhof M.G., Madrenas J. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 2006, 24:65-97.
29. Brazolot Millan C.L., Weeratna R., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15553-15558.
30. Chow Y.H., Chiang B.L., Lee Y.L., Chi W.K., Lin W.C., Chen Y.T., Tao M.H. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol. 1998, 160:1320-1329.
31. Boyle J.S., Koniaras C., Lew A.M. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int. Immunol. 1997, 9:1897-1906.
32. Iannacone M., Sitia G., Ruggeri Z.M., Guidotti L.G. HBV pathogenesis in animal models: recent advances on the role of platelets. J. Hepatol. 2007, 46:719-726.
33. Shoukry N.H., Cawthon A.G., Walker C.M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu. Rev. Microbiol. 2004, 58:391-424.
34. Norbury C.C., Sigal L.J. Cross priming or direct priming: is that really the question?. Curr. Opin. Immunol. 2003, 15:82-88.
35. Freigang S., Probst H.C., van den Broek M. DC infection promotes antiviral CTL priming: the "Winkelried" strategy. Trends Immunol. 2005, 26:13-18.
36. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
37. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995, 13:29-60.
38. Dandri M., Lutgehetmann M., Volz T., Petersen J. Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin. Liver Dis. 2006, 26:181-191.
39. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.